AZILECT er indiceret ved behandling af idiopatisk Parkinsons sygdom som monoterapi (uden levodopa) eller som kombinationsbehandling (med levodopa) hos patienter med end- of- dose fluktuationer.
AZILECT is indicated for the treatment of idiopathic Parkinson’ s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.